Get the Stockscreener App
41.56
0.95%
-0.40
After Hours:
41.26
-0.30
-0.72%
Ultragenyx Pharmaceutical Inc. Stock (RARE) Forecast
The Ultragenyx Pharmaceutical Inc. (RARE) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $39.49, representing a -4.97% decrease from the current price of $41.56. The highest analyst price target is $44.88, and the lowest is $34.11.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RARE Price Target
Average 29.06
(-30.07% Downside)
Is Ultragenyx Pharmaceutical Inc. (RARE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 36.76 | Neutral |
| STOCH(9,6) | 23.65 | Neutral |
| STOCHRSI(14) | 9.6457 | Buy |
| MACD(12,26) | -1.2611 | Sell |
| ADX(14) | 22.50 | Neutral |
| William %R | -88.81 | Buy |
| CCI(14) | -167.13 | Sell |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
43.04
Sell
|
42.93
Sell
|
| MA20 |
43.81
Sell
|
43.93
Sell
|
| MA50 |
46.77
Sell
|
45.38
Sell
|
| MA100 |
46.61
Sell
|
45.18
Sell
|
| MA200 |
42.09
Sell
|
44.41
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, RARE could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 12 signaling Sell signals and 3 Neutral signals. This might not be a good time to consider opening new positions on RARE, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 36.76 indicates that RARE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 23.65 indicates that RARE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 9.6457 indicates that RARE is oversold. This suggests that RARE price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 22.5 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -167.13 indicates that RARE is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term RARE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Ultragenyx Pharmaceutical Inc. financial reports and earnings history, Ultragenyx Pharmaceutical Inc. (RARE) stock could reach $23.34 by 2030, $6.4498 by 2040 and $15.12 by 2050. See the projected annual prices until 2050 of the Ultragenyx Pharmaceutical Inc. stock below:
- Ultragenyx Pharmaceutical Inc. (RARE) is expected to reach an average price of $10.17 in 2035, with a high prediction of $11.53 and a low estimate of $3.6245. This indicates an $-75.52% rise from the last recorded price of $41.56.
- Ultragenyx Pharmaceutical Inc. (RARE) stock is projected to chart a bullish course in 2040, with an average price target of $2.0466, representing an $-95.08% surge from its current level. The forecast ranges from a conservative $4.3566 to a sky-high $6.4498.
- Our analysts predict Ultragenyx Pharmaceutical Inc. (RARE) to jump -37.55% by 2045, soaring from $19.40 to an average price of $25.96, potentially reaching $20.98. While $19.40 is the low estimate, the potential upside is significant.
- Ultragenyx Pharmaceutical Inc. (RARE) stock is expected to climb by 2050, reaching an average of $13.74, a $-66.94% jump from its current level. However, a wide range of estimates exists, with high and low targets of $15.12 and $18.01, respectively, highlighting the market's uncertainty.
Ultragenyx Pharmaceutical Inc. Stock (RARE) Year by Year Forecast
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2024
Our forecast for RARE stock price in 2024 now indicates an average price target of $35.13 with a high forecast of $54.56 and a low forecast of $15.71. The average prediction reflects an decrease of -15.46% from the last recorded price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2024 | $43.00 | $34.11 | $44.88 | +3.45% |
| July, 2024 | $40.95 | $35.45 | $44.79 | -1.48% |
| August, 2024 | $35.68 | $32.76 | $43.63 | -14.16% |
| September, 2024 | $22.36 | $21.54 | $35.95 | -46.19% |
| October, 2024 | $23.36 | $21.50 | $25.48 | -43.79% |
| November, 2024 | $19.19 | $16.98 | $24.32 | -53.82% |
| December, 2024 | $23.43 | $15.71 | $23.97 | -43.62% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2025
Ultragenyx Pharmaceutical Inc. Stock (RARE) is expected to reach an average price of $48.18 in 2025, with a high prediction of $83.66 and a low estimate of $12.69. This indicates an +15.92% rise from the last recorded price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $23.64 | $21.25 | $26.44 | -43.11% |
| February, 2025 | $33.17 | $22.52 | $44.41 | -20.18% |
| March, 2025 | $34.41 | $31.35 | $44.85 | -17.20% |
| April, 2025 | $24.09 | $12.69 | $38.40 | -42.03% |
| May, 2025 | $43.87 | $23.26 | $45.44 | +5.56% |
| June, 2025 | $52.21 | $37.98 | $52.23 | +25.63% |
| July, 2025 | $58.48 | $46.30 | $58.53 | +40.71% |
| August, 2025 | $67.38 | $53.51 | $72.89 | +62.13% |
| September, 2025 | $66.05 | $56.31 | $71.35 | +58.92% |
| October, 2025 | $57.13 | $54.64 | $72.17 | +37.46% |
| November, 2025 | $63.60 | $54.17 | $68.12 | +53.03% |
| December, 2025 | $82.02 | $63.86 | $83.66 | +97.35% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2026
The predicted value for Ultragenyx Pharmaceutical Inc. (RARE) in 2026 is set at an average of $110.31. Estimates vary from a peak of $161.37 to a trough of $59.25, indicating an +165.42% surge from the present price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $104.03 | $72.71 | $105.97 | +150.31% |
| February, 2026 | $149.74 | $96.80 | $150.09 | +260.29% |
| March, 2026 | $119.76 | $113.60 | $161.37 | +188.15% |
| April, 2026 | $130.04 | $112.05 | $156.87 | +212.89% |
| May, 2026 | $106.72 | $92.60 | $130.58 | +156.78% |
| June, 2026 | $85.55 | $83.22 | $108.28 | +105.86% |
| July, 2026 | $93.07 | $81.71 | $101.70 | +123.93% |
| August, 2026 | $83.98 | $74.20 | $97.46 | +102.08% |
| September, 2026 | $73.73 | $70.05 | $87.80 | +77.40% |
| October, 2026 | $70.97 | $59.25 | $75.70 | +70.78% |
| November, 2026 | $78.85 | $59.88 | $80.53 | +89.73% |
| December, 2026 | $72.80 | $68.70 | $86.99 | +75.18% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Ultragenyx Pharmaceutical Inc. (RARE) is $50.58, with a high forecast of $72.42 and a low forecast of $28.74. This indicates an +21.70% increase from the last price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $61.18 | $58.59 | $72.42 | +47.22% |
| February, 2027 | $62.17 | $58.56 | $72.37 | +49.59% |
| March, 2027 | $67.81 | $55.79 | $69.40 | +63.17% |
| April, 2027 | $55.10 | $51.25 | $71.20 | +32.58% |
| May, 2027 | $51.76 | $45.47 | $56.14 | +24.54% |
| June, 2027 | $46.03 | $45.38 | $62.88 | +10.76% |
| July, 2027 | $55.96 | $44.50 | $56.96 | +34.65% |
| August, 2027 | $58.49 | $55.83 | $68.94 | +40.73% |
| September, 2027 | $32.18 | $28.74 | $59.84 | -22.57% |
| October, 2027 | $36.92 | $28.99 | $38.79 | -11.17% |
| November, 2027 | $49.86 | $37.10 | $50.06 | +19.97% |
| December, 2027 | $35.40 | $32.86 | $52.42 | -14.83% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2028
In 2028, Ultragenyx Pharmaceutical Inc. (RARE) is projected to reach an average price of $28.73, with a high projection of $39.90 and a low estimate of $17.57. This indicates an -30.87% fall from the last price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $31.67 | $30.18 | $37.44 | -23.80% |
| February, 2028 | $25.42 | $23.56 | $33.94 | -38.84% |
| March, 2028 | $24.58 | $20.77 | $27.41 | -40.86% |
| April, 2028 | $19.93 | $17.57 | $26.94 | -52.05% |
| May, 2028 | $27.84 | $19.01 | $30.52 | -33.02% |
| June, 2028 | $26.81 | $23.55 | $32.74 | -35.50% |
| July, 2028 | $28.49 | $26.34 | $32.42 | -31.44% |
| August, 2028 | $23.37 | $22.38 | $33.83 | -43.78% |
| September, 2028 | $24.30 | $20.37 | $26.68 | -41.52% |
| October, 2028 | $32.00 | $21.92 | $34.02 | -22.99% |
| November, 2028 | $35.74 | $30.98 | $37.00 | -13.99% |
| December, 2028 | $31.11 | $31.08 | $39.90 | -25.14% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2029
The 2029 price forecast for Ultragenyx Pharmaceutical Inc. Stock (RARE) is $28.69 on average, with a high prediction of $40.45 and a low estimate of $16.93. This represents an -30.97% decrease from the previous price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $28.21 | $26.12 | $32.09 | -32.11% |
| February, 2029 | $23.09 | $19.49 | $28.39 | -44.43% |
| March, 2029 | $22.95 | $21.21 | $27.25 | -44.77% |
| April, 2029 | $18.93 | $17.37 | $23.73 | -54.45% |
| May, 2029 | $20.36 | $16.93 | $25.44 | -51.01% |
| June, 2029 | $25.72 | $19.55 | $26.04 | -38.11% |
| July, 2029 | $33.47 | $25.01 | $35.58 | -19.47% |
| August, 2029 | $29.87 | $27.59 | $35.48 | -28.13% |
| September, 2029 | $35.33 | $28.04 | $36.07 | -14.99% |
| October, 2029 | $31.81 | $31.52 | $40.45 | -23.46% |
| November, 2029 | $28.42 | $27.12 | $38.59 | -31.62% |
| December, 2029 | $22.91 | $19.58 | $31.65 | -44.87% |
Ultragenyx Pharmaceutical Inc. Stock (RARE) Price Forecast for 2030
Ultragenyx Pharmaceutical Inc. Stock (RARE) is expected to reach an average price of $12.74 in 2030, with a high forecast of $25.46 and a low forecast of $0.0134. This signifies an -69.36% decrease from the last price of $41.56.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $17.02 | $13.81 | $23.34 | -59.05% |
| February, 2030 | $18.10 | $15.26 | $24.62 | -56.45% |
| March, 2030 | $16.00 | $15.83 | $23.73 | -61.51% |
| April, 2030 | $14.33 | $10.29 | $23.57 | -65.52% |
| May, 2030 | $3.1669 | $1.5725 | $14.82 | -92.38% |
| June, 2030 | $1.3146 | $0.1346 | $5.6258 | -96.84% |
| July, 2030 | $0.6484 | $0.0134 | $2.749 | -98.44% |
| August, 2030 | $4.2592 | $0.7746 | $6.7642 | -89.75% |
| September, 2030 | $15.27 | $2.3374 | $19.49 | -63.25% |
| October, 2030 | $22.19 | $12.12 | $25.41 | -46.62% |
| November, 2030 | $0.4315 | $1.8485 | $25.46 | -98.96% |
| December, 2030 | $9.3391 | $2.3247 | $11.53 | -77.53% |
0.91%
2.42%
Cap:
|
Volume (24h):